Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegsitacianine - OncoNano Medicine

Next Previous
X
Search
Drug Profile

Pegsitacianine - OncoNano Medicine

Alternative Names: ONM-100; ONM-100 DS

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer OncoNano Medicine
  • Class Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lung cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in Netherlands (IV, Injection)
  • 02 Jun 2023 Final adverse events and efficacy data from a phase-II trial in Peritoneal cancer presented at the59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023) (NCT04950166)
  • 27 Apr 2023 OncoNano Medicine plans pivotal trial in Peritoneal cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top